Aural Analytics and Koneksa Partner to Support Clinical Trials Using Speech Analytics
Aural Analytics, a speech analytics provider, has partnered with Koneksa, a provider of digital biomarker development, to further strengthen its platform and research capabilities using Aural Analytics Speech Vitals technology.
The technology would be used during clinical trials at scale across development and commercial pharmaceutical pipelines. The goal of this integration is to make it easy to add speech measures to Koneksa studies and digital biomarker development programs.
"Partnerships with leading digital research providers such as Koneksa strengthen our reach across the research ecosystem and advance our mission to develop best-in-class, clinical-grade speech analytics," said Judy Smythe, CEO of Aural Analytics, in a statement. "Koneksa and Aural Analytics share a vision in which speech analytics are an essential element of best-in-class digital biomarkers, which in time will further the fields of research and clinical care across neurodegenerative conditions."
"We're excited to work with Aural Analytics to integrate speech collection in our clinical trials," said Chris Benko, CEO and co-founder of Koneksa, in a statement. "Through this partnership, our teams will develop best-in-class digital biomarkers to pioneer a better care experience with a particular focus in neurodegenerative conditions."
The U.S. Food and Drug Administration has registered Aural Analytics' speech analytics as a computerized cognitive assessment aid.
Aural Analytics' speech analytics will help assess concussions following in-game injuries.
Medidata's Sensor Cloud Network will include Aural Analytics' Speech Vitals platform.
The NIH grant will support Aural Analytics work with Speech Vitals to deliver clinical-grade speech analytics.
Aural Analytics and Healint partner on integration of speech analytics into Healint's clinical trials and consumer applications.